A 12-year-old Girl with Severe Plaque Psoriasis and Down Syndrome Treated Successfully with Etanercept.
نویسندگان
چکیده
The association between Down syndrome and psoriasis is unclear. Immunological abnormalities that present in individuals with Down syndrome result in mild immune debilitation, thus the risk of infectious complications during immunosuppressive therapy might be higher in this group of patients. We present a case of 12-year-old girl with severe plaque psoriasis and Down syndrome, who was initially treated with cyclosporine with good response. However, the drug was withdrawn due to massive viral warts development and loss of efficacy. Afterwards, the girl was treated with etanercept in short 10 week and long 24 week courses with excellent response. The presented case is the first report of a child with Down syndrome and concomitant severe plaque psoriasis treated successfully with etanercept.
منابع مشابه
The treatment of psoriasis with etanercept: An experience from South Kuwait
The Gulf Journal of Dermatology and Venereology ABSTRACT Background: Etanercept, a tumor necrosis factor antagonist, is an approved biologic agent for treatment of chronic plaque psoriasis in the United States and Europe. Objective: To observe the efficacy and safety profile of etanercept in patients with moderate to severe plaque psoriasis. Methods: In this retrospective study, 56 patients wer...
متن کاملTreatment of psoriasis with etanercept in immunocompromised patients: Two case reports
Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and...
متن کاملA prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate to-severe chronic plaque-type psoriasis: the Psoriasis Infiximab vs. Etanercept Comparison Evaluation (PIECE) study
There are no direct comparison data between infliximab and entanercept in the treatment of psoriasis. This study was a mult icenter, randomised control trial done in the Netherlands to compare the efficacy, outcome of etanercept vs. infliximab in the management of moderate to severe chronic plaque psoriasis. Patients (age 1875 years old) with Psoriasis Area and Severity Index (PASI) ≥10 and/or ...
متن کاملSecukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study
TITLE Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), a randomized, placebo-controlled, phase 3 study. BACKGROUND Evidence has suggested Interleukin (IL)-17A to be an important effector cytokine...
متن کاملA cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
INTRODUCTION Biologic therapies have proven efficacious for patients with moderate-to-severe psoriasis. However, their economic value compared with standard of care in Italy has not been explored. This study estimates the cost-effectiveness of intermittent therapy with etanercept in patients with moderate-to-severe plaque-type psoriasis in comparison with nonsystemic therapy in Italy. METHODS...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Acta dermatovenerologica Croatica : ADC
دوره 25 2 شماره
صفحات -
تاریخ انتشار 2017